Exhibit 31.2
                                  CERTIFICATION

I, Simcha Edell, certify the following:

1.    I have reviewed this annual report on Form 10-KSB of Amazon Biotech, Inc.;

2.    Based on my knowledge, this annual report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this annual report;

3.    Based on my knowledge, the financial statements, and other financial
      information included in this annual report, fairly present in all material
      respects the financial condition, results of operations and cash flows of
      Amazon Biotech, Inc. as of, and for, the periods presented in this annual
      report;

4.    Amazon Biotech, Inc.'s other certifying officer and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Amazon Biotech,
      Inc. and we have done the following:

      a.    designed such disclosure controls and procedures, or caused such
            disclosure controls and procedures to be designed under our
            supervision, to ensure that material information relating to Amazon
            Biotech, Inc., including its consolidated subsidiaries, is made
            known to us by others within those entities, particularly during the
            period in which this annual report is being prepared;

      b.    designed such internal control over financial reporting, or caused
            such internal control over financial reporting to be designed under
            our supervision, to provide reasonable assurance regarding the
            reliability of financial reporting and the preparation of financial
            statements for external purposes in accordance with generally
            accepted accounting principles;

      c.    evaluated the effectiveness of Amazon Biotech, Inc.'s disclosure
            controls and procedures and presented in this annual report our
            conclusions about the effectiveness of the disclosure controls and
            procedures, as of the end of the period covered by this report based
            on such evaluation; and

      d.    disclosed in this annual report any change in Amazon Biotech, Inc.'s
            internal control over financial reporting that occurred during
            Amazon Biotech, Inc.'s fourth fiscal quarter that has materially
            affected, or is reasonably likely to materially affect, Amazon
            Biotech, Inc.'s internal control over financial reporting; and

<PAGE>

5.    Amazon Biotech, Inc.'s other certifying officer and I have disclosed,
      based on our most recent evaluation of internal control over financial
      reporting, to Amazon Biotech, Inc.'s auditors and the audit committee of
      the Amazon Biotech, Inc.'s board of directors:

      a.    all significant deficiencies and material weaknesses in the design
            or operation of internal control over financial reporting which are
            reasonably likely to adversely affect Amazon Biotech, Inc.'s ability
            to record, process, summarize and report financial information; and

      b.    any fraud, whether or not material, that involves management or
            other employees who have a significant role in Amazon Biotech,
            Inc.'s internal control over financial reporting.


November 14, 2005                              /s/ Simcha Edell
                                               ---------------------------------
                                                   Simcha Edell
                                                   Chief Financial Officer
                                                   (Principal Financial Officer)